Clinical Trial

A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially resectable HCC, assessed by the conversion resection rate.
Trial Details
NCT Number NCT07119931
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions HCC
Enrollment 34 participants
Start Date 2025-09-10
Primary Completion 2027-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-13